DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01165944

WithdrawnPhase 1, PHASE2

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Effectiveness of Pramlintide on Control of Post-Transplant Diabetes Mellitus

Asset

Pramlintide

Amylin analog

Listed sites

1

Recruiting sites

—

Enrollment

—

actual

Study population

Diabetes (other / unspecified)

Key I/E criterion

—

Primary endpoint

•HgA1c

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01165944
Org study ID08-1343

Timeline

Milestones

Study first posted2010-07-20estimated
Last update posted2018-07-26actual
Study start2009-08 (month precision)
Primary completion2011-08estimated (month precision)
Study completion2011-08estimated (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Diabetes (other / unspecified)

Eligibility

Who can enroll

Minimum age20 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Post-transplant diabetes (PTMD)
•Aged 20-70
•Diagnosis of diabetes within the last 6-18 months
•Stable medications
•Stable weight for 3 months
•Serum creatinine < 1.5 mg/dL

Exclusion criteria

•Pre-transplant diabetes
•Major postoperative complications following transplant
•Pregnancy
•Significant GI discomfort with nausea or vomiting
•Inability to learn continuous glucose monitoring
•Development of diabetes more than 4 years after transplant
•omen of child-bearing potential who use birth control pills and have fasting triglycerides of > 400 mg/dL

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

HgA1c

Time frame:6 months

descriptive, improvement

LOINC 4548-4

Secondary/protocol endpoint

Continuous glucose monitoring

Time frame:6 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.